Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy.
Authors
O'Reilly, EmilyCasey, Deborah
Ibrahim, Hisham
McGrath, Alice
McHugh, Tomás
Vairamani, Punitha
Murphy, Jill
Plant, Barry
Murphy, Desmond M
Issue Date
2022-07-11Keywords
ASTHMACORTICOSTEROIDS
TREATMENT
Metadata
Show full item recordJournal
Journal of asthma and allergyDOI
10.2147/JAA.S358321PubMed ID
35844776Item Type
ArticleLanguage
enISSN
1178-6965ae974a485f413a2113503eed53cd6c53
10.2147/JAA.S358321
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial 4.0 International
Related articles
- Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies.
- Authors: Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, Nissen F
- Issue date: 2021 Jul
- Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
- Authors: Kavati A, Zhdanava M, Ortiz B, Lecocq J, Schiffman B, Pilon D, Ho H, Lefebvre P, Stone B
- Issue date: 2019 Oct
- Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.
- Authors: Sullivan PW, Li Q, Bilir SP, Dang J, Kavati A, Yang M, Rajput Y
- Issue date: 2020 Jan
- Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence.
- Authors: Igarashi A, Kaur H, Choubey A, Popli A, Muthukumar M, Yoshisue H, Funakubo M, Ohta K
- Issue date: 2022 Jan-Feb
- Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
- Authors: Tarraf HN, Masoud HH, Zidan M, Wahba B
- Issue date: 2020 Feb